Other languages MAIA Biotechnology, Inc.

Equities

MAIA

US5526411021

Market Closed - Nyse Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
3.32 ^USD	+2.79%		-23.85%	+183.76%

Jun. 04	Maia Biotechnology Reveals New Clinical Data Showing Thio?s Strong Efficacy in Non-Small Cell Lung Cancer	CI
May. 21	MAIA Biotechnology, Inc. announced a financing transaction	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maia Biotechnology Reveals New Clinical Data Showing Thio?s Strong Efficacy in Non-Small Cell Lung Cancer	Jun. 04
MAIA Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Maia Biotechnology Insider Bought Shares Worth $299,409, According to a Recent SEC Filing	Apr. 26
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board	Mar. 21
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients	Mar. 08
MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC	Mar. 06
MAIA Biotechnology, Inc. Appoints Remus Vezan to its Scientific Advisory Board	Feb. 27
MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	Feb. 22
MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer	Feb. 07
Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds	Jan. 24
MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024	Jan. 17
Top Premarket Decliners	Jan. 12
MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer	Dec. 19
MAIA Biotechnology Closes $4 Million Direct Offering	Nov. 17
Top Midday Decliners	Nov. 15
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma	Nov. 13
MAIA Biotechnology Says Glioblastoma Treatment Gets Orphan-Drug Designation From US FDA	Nov. 10
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial	23-10-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MAIA Biotechnology, Inc.

Equities

MAIA

US5526411021

Other languages

Filters